Good News on Treatment & Prevention of COVID-19

A study in the New England Journal of Medicine (NEJM) examined the effects of a new vaccine which uses mRNA injections to stimulate an immune antibody response against the coronavirus. The published study looked at two potential dosages while looking at younger patients and those over 65 years old.

Both doses of the injection vaccine produced an antibody response in the younger patients and senior adults. Side effects were minimal – mostly injection site irritation and soreness. Some patients ran low grade fevers and had myalgias. The vaccine is now in a larger Phase 3 trial.

This vaccine and another mRNA product in testing and production both have the drawback of requiring storage at -40 to -80 centigrade which most pharmacies and physician facilities do not routinely provide. It is hoped this vaccine will be available by the end of year 2020. There have been no challenge tests with this vaccine, meaning vaccinated individuals who develop antibodies have not been directly exposed to the coronavirus to see if those levels of immunity are protective.

On the same day of the publication of the NEJM study on the mRNA vaccine, the pharmaceutical company Regeneron released a shareholder report on its Phase1 and 2 IV anti COVID-19 monoclonal antibody. They took antibodies from recovered COVID-19 patients, identified the most important ones and then synthetically created duplicates of two of the more important antibodies in a form that is infused by IV administration. This product blocks the P spike on the coronavirus from working, preventing the coronavirus from attaching to and entering human cells.

They enrolled COVID-19 infected patients with symptoms but not severe enough to require hospitalization. They found that those with a low viral load of the disease developed an immune response with IgG antibodies to COVID-19. Those who had few or no antibodies were overwhelmed by the virus and had high viral loads measured. They found that the Regeneron product worked best in those with a high viral load and few or absent antibodies to COVID-19 virus and more symptoms. These patients cleared the virus quicker with the monoclonal antibody product than non-medicated patients receiving standard care. They had alleviation of symptoms quicker and tolerated the infusion and product well.

In addition to this trial on non-hospitalized patients there is currently an ongoing trial in hospitalized patients in Phase 2 and 3.There is additionally a trial in family members of COVID-19 positive patients to see if the Regeneron monoclonal antibodies can prevent them from acquiring the virus in close household contact.

There is light at the end of the tunnel. We just need to continue to social distance, wear masks in public settings, hand wash frequently and remain patient because these products are very close to release.